12/5
05:04 pm
kymr
Kymera Therapeutics to Announce KT-621 BroADen Phase 1b Atopic Dermatitis Trial Results on December 8, 2025 [Yahoo! Finance]
Medium
Report
Kymera Therapeutics to Announce KT-621 BroADen Phase 1b Atopic Dermatitis Trial Results on December 8, 2025 [Yahoo! Finance]
12/5
04:01 pm
kymr
Kymera Therapeutics to Announce KT-621 BroADen Phase 1b Atopic Dermatitis Trial Results on December 8, 2025
Medium
Report
Kymera Therapeutics to Announce KT-621 BroADen Phase 1b Atopic Dermatitis Trial Results on December 8, 2025
11/26
11:07 am
kymr
Kymera Therapeutics (NASDAQ:KYMR) was given a new $80.00 price target on by analysts at Truist Financial Corporation.
Low
Report
Kymera Therapeutics (NASDAQ:KYMR) was given a new $80.00 price target on by analysts at Truist Financial Corporation.
11/26
07:19 am
kymr
Kymera Therapeutics (NASDAQ:KYMR) was given a new $90.00 price target on by analysts at UBS Group AG. They now have a "buy" rating on the stock.
Low
Report
Kymera Therapeutics (NASDAQ:KYMR) was given a new $90.00 price target on by analysts at UBS Group AG. They now have a "buy" rating on the stock.
11/25
07:00 am
kymr
Kymera Therapeutics Announces First Patient Dosed in BROADEN2 Phase 2b Atopic Dermatitis Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader
Low
Report
Kymera Therapeutics Announces First Patient Dosed in BROADEN2 Phase 2b Atopic Dermatitis Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader
11/24
07:00 am
kymr
Kymera Therapeutics to Participate in Upcoming December Investor Conferences
Low
Report
Kymera Therapeutics to Participate in Upcoming December Investor Conferences
11/10
03:32 pm
kymr
Kymera Therapeutics, Inc. (KYMR) Presents at UBS Global Healthcare Conference 2025 Transcript [Seeking Alpha]
Low
Report
Kymera Therapeutics, Inc. (KYMR) Presents at UBS Global Healthcare Conference 2025 Transcript [Seeking Alpha]
11/5
10:07 am
kymr
Kymera Therapeutics (NASDAQ:KYMR) had its price target raised by analysts at Wells Fargo & Company from $53.00 to $69.00. They now have an "overweight" rating on the stock.
Low
Report
Kymera Therapeutics (NASDAQ:KYMR) had its price target raised by analysts at Wells Fargo & Company from $53.00 to $69.00. They now have an "overweight" rating on the stock.
11/5
07:19 am
kymr
Kymera Therapeutics (NASDAQ:KYMR) had its "overweight" rating reaffirmed by analysts at Barclays PLC.
Low
Report
Kymera Therapeutics (NASDAQ:KYMR) had its "overweight" rating reaffirmed by analysts at Barclays PLC.
11/5
07:19 am
kymr
Kymera Therapeutics (NASDAQ:KYMR) had its "buy" rating reaffirmed by analysts at HC Wainwright.
Low
Report
Kymera Therapeutics (NASDAQ:KYMR) had its "buy" rating reaffirmed by analysts at HC Wainwright.
11/4
04:07 pm
kymr
Kymera Therapeutics (NASDAQ:KYMR) had its "outperform" rating reaffirmed by analysts at Oppenheimer Holdings, Inc..
Low
Report
Kymera Therapeutics (NASDAQ:KYMR) had its "outperform" rating reaffirmed by analysts at Oppenheimer Holdings, Inc..
11/4
04:07 pm
kymr
Kymera Therapeutics (NASDAQ:KYMR) had its "overweight" rating reaffirmed by analysts at Morgan Stanley.
Low
Report
Kymera Therapeutics (NASDAQ:KYMR) had its "overweight" rating reaffirmed by analysts at Morgan Stanley.
11/4
02:08 pm
kymr
Kymera Therapeutics (NASDAQ:KYMR) had its "buy" rating reaffirmed by analysts at Jefferies Financial Group Inc..
Low
Report
Kymera Therapeutics (NASDAQ:KYMR) had its "buy" rating reaffirmed by analysts at Jefferies Financial Group Inc..
11/4
07:00 am
kymr
Kymera Therapeutics Announces Third Quarter 2025 Financial Results and Provides a Business Update
Medium
Report
Kymera Therapeutics Announces Third Quarter 2025 Financial Results and Provides a Business Update
11/4
05:49 am
kymr
Kymera Therapeutics (NASDAQ:KYMR) was upgraded by analysts at Guggenheim to a "strong-buy" rating.
Medium
Report
Kymera Therapeutics (NASDAQ:KYMR) was upgraded by analysts at Guggenheim to a "strong-buy" rating.
11/3
07:00 am
kymr
Kymera Therapeutics to Participate in Upcoming November Investor Conferences
Medium
Report
Kymera Therapeutics to Participate in Upcoming November Investor Conferences
11/3
06:03 am
kymr
Kymera Therapeutics (NASDAQ:KYMR) was given a new $90.00 price target on by analysts at Guggenheim.
Medium
Report
Kymera Therapeutics (NASDAQ:KYMR) was given a new $90.00 price target on by analysts at Guggenheim.
10/28
07:00 am
kymr
Kymera Therapeutics to Report Third Quarter 2025 Financial Results on November 4, 2025
Low
Report
Kymera Therapeutics to Report Third Quarter 2025 Financial Results on November 4, 2025
10/27
07:00 am
kymr
Kymera Therapeutics Presents New Preclinical Data for KT-579, a First-in-Class, Oral IRF5 Degrader, at the American College of Rheumatology Annual Meeting
Medium
Report
Kymera Therapeutics Presents New Preclinical Data for KT-579, a First-in-Class, Oral IRF5 Degrader, at the American College of Rheumatology Annual Meeting
10/24
08:36 am
kymr
Kymera Therapeutics (NASDAQ:KYMR) had its price target raised by analysts at B. Riley from $60.00 to $80.00. They now have a "buy" rating on the stock.
Low
Report
Kymera Therapeutics (NASDAQ:KYMR) had its price target raised by analysts at B. Riley from $60.00 to $80.00. They now have a "buy" rating on the stock.
10/23
06:16 am
kymr
Kymera Therapeutics (NASDAQ:KYMR) was upgraded by analysts at Mizuho to a "strong-buy" rating.
Medium
Report
Kymera Therapeutics (NASDAQ:KYMR) was upgraded by analysts at Mizuho to a "strong-buy" rating.
10/22
08:04 am
kymr
Kymera Therapeutics (NASDAQ:KYMR) had its price target raised by analysts at BTIG Research from $59.00 to $75.00. They now have a "buy" rating on the stock.
Medium
Report
Kymera Therapeutics (NASDAQ:KYMR) had its price target raised by analysts at BTIG Research from $59.00 to $75.00. They now have a "buy" rating on the stock.
10/21
08:03 am
kymr
Kymera Therapeutics (NASDAQ:KYMR) is now covered by analysts at Mizuho. They set an "outperform" rating and a $81.00 price target on the stock.
Medium
Report
Kymera Therapeutics (NASDAQ:KYMR) is now covered by analysts at Mizuho. They set an "outperform" rating and a $81.00 price target on the stock.
10/17
07:20 am
kymr
Kymera Therapeutics (NASDAQ:KYMR) had its "buy" rating reaffirmed by analysts at Citigroup Inc..
Low
Report
Kymera Therapeutics (NASDAQ:KYMR) had its "buy" rating reaffirmed by analysts at Citigroup Inc..
10/1
08:47 am
kymr
Kymera Therapeutics (NASDAQ:KYMR) was given a new $63.00 price target on by analysts at Oppenheimer Holdings, Inc..
Medium
Report
Kymera Therapeutics (NASDAQ:KYMR) was given a new $63.00 price target on by analysts at Oppenheimer Holdings, Inc..